Navigation Links
Delcath on Preliminary List of Additions to Russell Microcap® Index
Date:6/13/2011

NEW YORK, June 13, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it expects to be added to the Russell Microcap® Index according to a preliminary list of additions posted on June 10, 2011 at www.russell.com/indexes, and will remain a component of the Russell 3000® and Russell 2000® Indexes, when Russell Investments reconstitutes its family of U.S. indexes on June 24, 2011 after the close of the U.S. markets.

The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market and is comprised of the smallest 1,000 companies in the Russell 3000 Index, plus the next smallest 1,000 companies.  Inclusion in the Russell Microcap Index will remain in place for the ensuing 12-month period.  The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. According to Russell Investments, $3.9 trillion in institutional assets currently are benchmarked to its indexes.  The indexes are reconstituted annually.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company received CE Mark approval for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any,  for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities, and uncertainties relating to the impact, if any, of being added to the Russell Microcap Index. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are madeContact Information:Investor Contact:

Media Contact:Doug Sherk/Gregory Gin

Janine McCargoEVC Group

EVC Group415-896-6818/646-445-4801

646-688-0425
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath to Present at the JMP Securities Research Conference
2. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
3. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
4. Delcath to Update Investors on FDA Meeting
5. Delcath Expands Board of Directors With Appointment of Gabriel Leung
6. Delcath to Present at Upcoming Investor Conferences
7. Delcath Systems Receives Refusal to File Letter From FDA
8. Delcath Achieves ISO 13485 Certification
9. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
10. Delcath Systems Announces Third Quarter Progress Report Conference Call
11. Delcath Strengthens Research and Development Team with Key Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... May 11, 2017  Thornhill Research Inc. ( ... awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract ... Canadian Commercial Corporation (CCC) ( Ottawa, Ontario, ... to administer general anesthesia to patients requiring emergency ... "The US Marine Corps have been a longtime ...
(Date:5/10/2017)... -- Radiology has become the number one diagnostic tool ... to the number one ranking as a result.  More ... as the most complete and reliable method for clinical ... pain an MRI may confirm a suspected herniated disc ... entirely different treatment protocols.  In these circumstances, patients need ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs included on ... health systems in the nation and help their organizations navigate the challenges in ... been instrumental in developing successful hospital and health system strategy. , Becker's Hospital ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Technique, technique, technique ... injury when either lifting weights for strength training and exercise or simply lifting heavy ... . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting anything ...
(Date:5/23/2017)... ... 23, 2017 , ... MDLand International (MDLand), a leading Electronic ... its iClinic V12.2 solution has achieved approval from National Center for Quality Assurance ... standards which emphasize team-based care with a significant focus on the care management ...
(Date:5/23/2017)... ... 2017 , ... Allegheny Health Network and the Alexis Joy ... Women’s Behavioral Health at West Penn Hospital , a unique facility that will ... pregnancy-related depression. Construction of the Center is underway with a scheduled opening in ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, ... remained steady since 2009, according to a Workers Compensation Research Institute (WCRI) study, ... Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity ...
Breaking Medicine News(10 mins):